Department of Gastroenterology and Hepatology, Osaka Red Cross Hospital, Osaka, Japan
Department of Gastroenterology and Hepatology, Osaka Red Cross Hospital, Osaka, Japan.
Anticancer Res. 2014 Dec;34(12):6877-86.
Palliative therapies for hepatocellular carcinoma (HCC) include transcatheter arterial embolic therapies, radiation therapy and systemic chemotherapies such as sorafenib. Conventional transcatheter arterial chemoembolization (cTACE) is the golden standard for the treatment of intermediate-stage HCC, and involves the administration of chemotherapuetic drugs, with or without lipiodol, by means of a catheter directly to the feeding artery of the targeted tumor followed by administration of embolic agents, while the concept of drug-eluting bead TACE (DEB-TACE) builds on the rationale for cTACE. DEB-TACE has been demonstrated to substantially improve the pharmacokinetic profile of TACE, providing levels of consistency and repeatability in patients that are not available with cTACE. On the other hand, the technique of radioembolization therapy for HCC involves the delivery of high-dose radiation via the hepatic artery. In the present review, we summarize the current status of these transcatheter arterial embolic therapies in HCC.
肝细胞癌（HCC）的姑息治疗方法包括经导管动脉栓塞治疗、放射治疗和索拉非尼等系统化疗。传统的经导管动脉化疗栓塞（cTACE）是治疗中期 HCC 的金标准，通过导管将化疗药物直接注入靶向肿瘤的供血动脉，然后注入栓塞剂，同时使用或不使用碘化油，而载药微球 TACE（DEB-TACE）的概念基于 cTACE 的原理。DEB-TACE 已被证明可显著改善 TACE 的药代动力学特征，为患者提供 cTACE 无法提供的一致性和可重复性水平。另一方面，HCC 的放射性栓塞治疗技术涉及通过肝动脉输送高剂量辐射。在本综述中，我们总结了这些经导管动脉栓塞治疗 HCC 的现状。
